Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 3,850,000 shares, a decline of 8.3% from the December 31st total of 4,200,000 shares. Currently, 6.7% of the company's stock are sold short. Based on an average daily trading volume, of 606,000 shares, the days-to-cover ratio is currently 6.4 days.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $0.34 during mid-day trading on Tuesday, reaching $121.63. The company's stock had a trading volume of 419,905 shares, compared to its average volume of 501,137. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm's 50-day moving average is $122.62 and its two-hundred day moving average is $116.28. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a market cap of $7.35 billion, a P/E ratio of 17.13, a PEG ratio of 0.90 and a beta of 0.56.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now owns 427,025 shares of the company's stock, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,253 shares of company stock worth $890,594 in the last three months. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JAZZ. Bank of New York Mellon Corp raised its stake in Jazz Pharmaceuticals by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock worth $58,835,000 after acquiring an additional 24,481 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth about $25,000. Waterfront Wealth Inc. increased its position in shares of Jazz Pharmaceuticals by 1.4% during the 4th quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company's stock worth $1,191,000 after purchasing an additional 137 shares in the last quarter. Convergence Investment Partners LLC bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $1,033,000. Finally, Cardinal Capital Management boosted its position in Jazz Pharmaceuticals by 5.1% in the fourth quarter. Cardinal Capital Management now owns 13,140 shares of the specialty pharmaceutical company's stock valued at $1,618,000 after buying an additional 641 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Analyst Ratings Changes

JAZZ has been the topic of several analyst reports. Piper Sandler reiterated an "overweight" rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. TD Cowen decreased their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a report on Thursday, November 7th. Needham & Company LLC reiterated a "buy" rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.